Provirex
PROVIREX GmbH, a privately-held biotech firm, specializes in developing first-in-class advanced therapy medicinal products (ATMPs).
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
* | N/A | Grant | |
| Total Funding | 000k | ||
Related Content
PROVIREX Genome Editing Therapies GmbH is a pioneering biotech company dedicated to developing groundbreaking genome editing therapies for the cure of HIV. Our core technology harnesses highly specific designer recombinases—such as Brec1—to precisely remove integrated HIV DNA from infected cells. Unlike conventional gene editing methods, our recombinase-based approach achieves exceptional accuracy and safety by directly excising viral genomes without relying on cellular DNA repair mechanisms.
At our unique therapy hub in Hamburg, we operate Europe’s only S3** biosafety cleanrooms specifically designed for advanced therapy medicinal product (ATMP) manufacturing. This integrated facility sets new standards for safety and quality, enabling the development and clinical application of innovative, personalized HIV therapies. Our passionate team combines scientific excellence and innovative spirit to transform the future of HIV therapy.